Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Murphy, M.
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Murphy, M.
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Foreword

M. Murphy1 and J. Shepherd*,2

1 Department of Pharmacology and Therapeutics, National University of Ireland, University College Cork, Cork, Ireland
2 Department of Pathological Biochemistry, Royal Infirmary, Glasgow, Scotland, UK

* Correspondence: Professor James Shepherd, Department of Pathological Biochemistry, Royal Infirmary, Glasgow G4 0SF, UK.

References

  1. The Scandinavian Simvastatin Survival Study. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389[CrossRef][Web of Science][Medline]
  2. Sacks FM, Pfeffer MA, Moye LA, et al. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol. 1991;68:1436–1446[CrossRef][Web of Science][Medline]
  3. Sacks FM, Pfeffer MA, Moye LA, et al, Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol levels. N Engl J Med. 1996;335:1001–1009[Abstract/Free Full Text]
  4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad base of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357[Abstract/Free Full Text]
  5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–1307[Abstract/Free Full Text]
  6. Downs JR, Clearfield M, Weis S, et alAFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622[Abstract/Free Full Text]
  7. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol. 1999;84:1192–1197[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Murphy, M.
Right arrow Articles by Shepherd, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Murphy, M.
Right arrow Articles by Shepherd, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?